Association of HDL-related loci with age-related macular degeneration and plasma lutein and zeaxanthin: the Alienor study

Several genes implicated in high-density lipoprotein (HDL) metabolism have been reported to be associated with age-related macular degeneration (AMD). Furthermore, HDL transport the two carotenoids, lutein and zeaxanthin, which are highly suspected to play a key-role in the protection against AMD. T...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 8; no. 11; p. e79848
Main Authors: Merle, Bénédicte M J, Maubaret, Cécilia, Korobelnik, Jean-François, Delyfer, Marie-Noëlle, Rougier, Marie-Bénédicte, Lambert, Jean-Charles, Amouyel, Philippe, Malet, Florence, Le Goff, Mélanie, Dartigues, Jean-François, Barberger-Gateau, Pascale, Delcourt, Cécile
Format: Journal Article
Language:English
Published: United States Public Library of Science 06-11-2013
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several genes implicated in high-density lipoprotein (HDL) metabolism have been reported to be associated with age-related macular degeneration (AMD). Furthermore, HDL transport the two carotenoids, lutein and zeaxanthin, which are highly suspected to play a key-role in the protection against AMD. The objective is to confirm the associations of HDL-related loci with AMD and to assess their associations with plasma lutein and zeaxanthin concentrations. Alienor study is a prospective population-based study on nutrition and age-related eye diseases performed in 963 elderly residents of Bordeaux, France. AMD was graded according to the international classification, from non-mydriatic colour retinal photographs. Plasma lutein and zeaxanthin were determined by normal-phase high-performance liquid chromatography. The following polymorphisms were studied: rs493258 and rs10468017 (LIPC), rs3764261 (CETP), rs12678919 (LPL) and rs1883025 (ABCA1). After multivariate adjustment, the TT genotype of the LIPC rs493258 variant was significantly associated with a reduced risk for early and late AMD (OR=0.64, 95%CI: 0.41-0.99; p=0.049 and OR=0.26, 95%CI: 0.08-0.85; p=0.03, respectively), and with higher plasma zeaxanthin concentrations (p=0.03), while plasma lipids were not significantly different according to this SNP. Besides, the LPL variant was associated with early AMD (OR=0.67, 95%CI: 0.45-1.00; p=0.05) and both with plasma lipids and plasma lutein (p=0.047). Associations of LIPC rs10468017, CETP and ABCA1 polymorphisms with AMD did not reach statistical significance. These findings suggest that LIPC and LPL genes could both modify the risk for AMD and the metabolism of lutein and zeaxanthin.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: All authors have completed the Unified Competing Interest form and declare: B MJ Merle received grants from Conseil Regional d'Aquitaine, received payment for lectures from Laboratoires Théa and Bausch+Lomb and travel accommodations from laboratoires Théa. C Maubaret received grant from Fondation pour la recherche médicale. JF Korobelnik received consulting fees from Laboratoires Théa and is board membership for Alcon, Allergan, Carl Zeiss Meditec, Bayer and Novartis. MN Delyfer received consulting fees from Laboratoires Théa and travel accommodation from Novartis. MB Rougier is consultant for Allegan, Bausch+Lomb and received payment for lectures from Laboratoires Théa, Biogen and Novartis. JC Lambert: None. P Amouyel is board membership for Fondation Plan Alzheimer, consultant for Servier, Total and Alzprotect, received grant from Ipsen, Sanofi Aventis and Astra Zeneca, had stock option from GenoScreen. F Malet: none. M LeGoff: none. JF Dartigues is board membership for Novastis, Ispen and Merk Serono and received grant from Novartis, Ipen and Lundbeck. P Barberger-Gateau received consulting fees from Vifor Pharma and received grants from Danone Research, Groupe Lipides et Nutrition and Nutricia. C Delcourt is board membership for Laboratoires Théa and received consulting fees from Bausch+Lomb and Novartis. Laboratoires Théa partly funded this study. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: JFK MND MBR FM JFD PBG CD. Performed the experiments: JFK MND MBR FM JCL PA JFD PBG CD. Analyzed the data: BM CM MLG PBG CD. Contributed reagents/materials/analysis tools: JFK MND MBR FM JCL PA JFD PBG CD. Wrote the manuscript: BM CM CD.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0079848